YOLFTbeta
Nasus Pharma Ltd.

Nasus Pharma Ltd.

NSRX · AMEX · Healthcare / Drug Manufacturers - General

2.87USD+0.05 (+1.77%)

Price History

Full chart

Market Stats

Previous Close2.82
Open2.94
Day Range2.81 – 2.94
52-Week Range1.98 – 9.50
Volume4.68K
Market Cap42.05M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.13
Dividend Yield0.00%
50-Day Avg3.52
200-Day Avg4.10

About

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Ehud Moshe Gilboa MBA
  • Employees7
  • HeadquartersYigal Alon 65, Tel Aviv-Yafo, Israel, 6744317, USA
  • Websitehttps://www.nasuspharma.com

Leadership

  • Mr. Ehud Moshe Gilboa MBACo-Founder & Executive Chairman · b. 1966

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Operating Income-2.04M-1.15M-1.08M-4.90M
EBITDA-2.13M-956.00K-1.52M-4.90M
Net Income-1.71M-1.05M-1.53M-5.86M
R&D1.12M567.00K335.00K2.24M
Interest Expense18.00K49.00K29.00K-

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets417.00K444.00K717.00K5.00M
Total Liabilities3.20M4.24M3.93M2.24M
Total Equity-2.79M-3.80M-3.21M2.77M
Cash154.00K193.00K284.00K1.24M
Total Debt---118.00K
Net Debt1.42M2.26M1.52M-1.12M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.21M-1.03M-665.00K-4.92M
Investing Cash Flow-160.00K---3.01M
Financing Cash Flow1.24M1.05M770.00K8.92M
Capital Expenditure00014.00K
Free Cash Flow-1.21M-1.03M-665.00K-4.93M
FCF to OCF100.00%100.00%100.00%100.28%

Earnings

Report DateMar 21, 2025Sep 3, 2025Dec 3, 2025Feb 25, 2026Mar 31, 2026Jun 30, 2026
EPS Estimate0.000.00-0.14-0.53-0.23-0.23
EPS Actual-0.09-0.09-0.140.00--0.54
Surprise--0.00%100.00%--134.78%
Timing------

Key Statistics & Ratios

Market Cap42.05M
Enterprise Value30.10M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.80
EPS-1.13
Book Value0.939
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-316.04%
Return on Assets-96.73%
Shares Outstanding11.71M
Shares Float5.46M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%